Line separator




From our October 2021 Newsletter

EndTB clinical trial for multidrug-resistant TB completes enrollment
Hundreds of patient volunteers from four continents have enrolled in a trial that aims to find safer, shorter, and effective treatments for multidrug-resistant tuberculosis (MDR-TB), an airborne, infectious disease that has grown resistant to standard medications. A group of scientists and clinicians led by Médecins Sans Frontières (MSF), Partners In Health (PIH) and Interactive Research and Development (IRD) make up the endTB consortium conducting the groundbreaking study funded by Unitaid.

Largest ever global study of tuberculosis identifies genetic causes of drug resistance
Using cutting-edge genomic sequencing techniques, researchers at the University of Oxford have identified almost all the genomic variation that gives people resistance to 13 of the most common tuberculosis (TB) drug treatments.

Clinical trial results offer hope to DR-TB patients with short, effective treatment
TB-PRACTECAL, a clinical trial led by Médecins Sans Frontières (MSF), has found that a new, all-oral, six-month treatment regimen is safer and more effective at treating rifampicin-resistant tuberculosis (RR-TB) than the current accepted standard of care. These results signal the start of a new chapter for people with drug-resistant (DR)-TB, who currently face lengthy treatment regimens.

From our September 2021 Newsletter

How COVID is derailing the fight against HIV, TB, and Malaria
The COVID-19 pandemic has had a “devastating” impact on the fight against other deadly infectious diseases, according to a report that compares 2019 and 2020 data on HIV, tuberculosis (TB) and malaria in more than 100 low- and lower-middle-income countries.

Innovative tools take aim at antibiotic-resistant microbes
Diagnostics that rely on bacterial movements, genomics and machine learning could help to address a global crisis.

Fighting tuberculosis with medication, mental health, and social support 
In Zhytomyr, Ukraine, our teams works with the Regional TB Dispensary to treat patients who have drug-resistant forms of tuberculosis (DR-TB). They are treated with a short course of DR-TB medication and the possibility of being treated at home most of the time; meaning patients can get back to their lives, families and careers sooner. Yet, completing the new treatments can still be tough.


From our August 2021 Newsletter


No News This Month!

From our July 2021 Newsletter

New Trial Results Show Effectiveness of BPaL Regimen for Highly Drug- Resistant TB Can Be Maintained with Reduced Dosing of Linezolid

The results of ZeNix, a Phase 3 clinical trial that took place in 11 sites across Georgia, Moldova, Russia, and South Africa, revealed that the BPaL treatment remains effective against highly drug-resistant strains of tuberculosis (TB) with either reduced dosage or duration of the linezolid component of the regimen.1Simultaneously, with the maintenance of efficacy, there was a decrease in linezolid associated side effects.

From our June 2021 Newsletter

Shorter treatment regime found to be effective for treating drug-susceptible TB.
A research team led by a Medical University of South Carolina (MUSC) investigator reports in the May 6 issue of the New England Journal of Medicine that a four-month treatment regimen using rifapentine is effective for treating TB. Shortening the treatment duration is an important step toward increased patient adherence.

Low-Dose Amikacin as Alternative Treatment for Multidrug-Resistant Tuberculosis
Low-dose amikacin with appropriate dose adjustment based on adequate monitoring demonstrated limited toxicity with positive outcomes as a treatment option for multidrug-resistant tuberculosis (MDR-TB), according to the findings of a retrospective cohort study published in BMC Infectious Diseases.

WHO releases new global lists of high-burden countries for TB, HIV-associated TB and drug-resistant TB.
The World Health Organization (WHO) today released updated global lists of high burden countries for tuberculosis (TB), HIV-associated TB and multidrug/rifampicin-resistant TB (MDR/RR-TB). The new lists are for 2021–2025 and replace those previously used between 2016 and 2020.

From our May 2021 Newsletter

 Tailor-made therapy of multi-resistant tuberculosis
The successful treatment of multidrug-resistant tuberculosis requires clarification in advance as to which antibiotics the pathogens are resistant to. Classic testing in the laboratory is very time-consuming and delays the start of therapy. Researchers from the Research Center Borstel, the Leibniz Lung Center, and the German Center for Infection Research (DZIF) have now prepared a catalogue of all mutations in the genome of tuberculosis bacteria and on the basis of a genome sequencing can quickly and cheaply predict which medicines are most effective for tuberculosis treatment. 


From our April 2021 Newsletter

Drug-Resistant TB Trial Stopped Early After Successful Results 

Médecins Sans Frontières (MSF/Doctors Without Borders) announced early closure of its phase 2/3 trial of a 6 month multidrug regimen for multidrug-resistant tuberculosis (MDR-TB) because an independent data safety and monitoring board (DSMB) determined that the drug combination in the study regimen was superior to current therapy, according to a press release.

From our February 2020 Newsletter

WHO announces updates on new molecular assays for the diagnosis of tuberculosis (TB) and drug resistance

Significant advances to the diagnosis of tuberculosis (TB) and drug resistance in adults, adolescents and children are expected, following key updates on new molecular assays, announced by the World Health Organization (WHO) in a rapid communication released today.